Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: Implications for gene therapy

Authors

  • Sander van der Marel MD,

    Corresponding author
    1. Research and Development, Amsterdam Molecular Therapeutics (AMT) B.V., Amsterdam, the Netherlands
    2. Department of Gastroenterology & Hepatology, Leiden University Medical Center, Leiden, the Netherlands
    • Research and Development, Amsterdam Molecular Therapeutics (AMT) B.V., Meibergdreef 61, 1105 BA Amsterdam, the Netherlands
    Search for more papers by this author
  • Elisabeth M. Comijn BSc,

    1. Research and Development, Amsterdam Molecular Therapeutics (AMT) B.V., Amsterdam, the Netherlands
    Search for more papers by this author
  • Hein W. Verspaget PhD,

    1. Department of Gastroenterology & Hepatology, Leiden University Medical Center, Leiden, the Netherlands
    Search for more papers by this author
  • Sander van Deventer MD, PhD,

    1. Research and Development, Amsterdam Molecular Therapeutics (AMT) B.V., Amsterdam, the Netherlands
    2. Department of Gastroenterology & Hepatology, Leiden University Medical Center, Leiden, the Netherlands
    Search for more papers by this author
  • Gijs R. van den Brink MD, PhD,

    1. Department of Gastroenterology & Hepatology, Academic Medical Center, Amsterdam, the Netherlands
    2. Tytgat Institute for Liver and Intestinal disease, Academic Medical Center, Amsterdam, the Netherlands
    Search for more papers by this author
  • Harald Petry PhD,

    1. Research and Development, Amsterdam Molecular Therapeutics (AMT) B.V., Amsterdam, the Netherlands
    Search for more papers by this author
  • Daniel W. Hommes MD, PhD,

    1. Department of Gastroenterology & Hepatology, Leiden University Medical Center, Leiden, the Netherlands
    Search for more papers by this author
  • Valerie Ferreira PhD

    1. Research and Development, Amsterdam Molecular Therapeutics (AMT) B.V., Amsterdam, the Netherlands
    Search for more papers by this author

  • Conflict-of-interest disclosure: Three of the authors are employees of AMT (E.C., H.P., and V.S.). S.M. currently works in the lab of AMT. S.D. is a board member of AMT.

  • Sander van der Marel (S.M.) and Daniel W. Hommes (D.H.) are supported by a grand from the Broad Foundation (Proposal No. IBD-029 5R).

Abstract

Background:

Inflammatory bowel diseases (IBDs) are comprised of two major disorders: Crohn's disease (CD) and ulcerative colitis (UC). No curative treatment options are available, but gene therapy may offer an alternative therapeutic approach. For this a safe and reliable vector is needed. The adeno-associated viruses (AAV) have attracted considerable interest as gene therapy vectors. However, neutralizing antibodies (nAb's) made in response to wildtype AAV have been associated with a partial to complete block of transduction in case of reexposure. Therefore, and in order to define AAV vector candidates to treat IBD patients, we characterized preexisting humoral responses to AAV in this population.

Methods:

We measured circulating antibodies against AAV serotypes 1, 2, 3, 4, 5, 6, and 8 using a previously established virus neutralization assay. In all, 100 healthy donors and 200 IBD patient's serum samples (101 CD and 99 UC) were analyzed.

Results:

A significant difference was detected in the prevalence of nAb's for AAV types 1, 5, 6, and 8 between the healthy donors and the patient population. Furthermore, various disease phenotypic characteristics correlated with the prevalence of nAb's to all the serotypes studied.

Conclusions:

Our study establishes a foundation for the development of an AAV-based gene therapy approach as a novel treatment for IBD. Furthermore, we show a relationship between disease phenotype in IBD patients and the humoral immune response to AAV. (Inflamm Bowel Dis 2011;)

Ancillary